Predict your next investment

Corporation
HEALTHCARE | Biotechnology
cellectis.com

See what CB Insights has to offer

Founded Year

1999

Stage

IPO | IPO

Date of IPO

3/25/2015

Market Cap

0.28B

Revenue

$0000 

About Cellectis

Cellectis is a gene-editing company, employing proprietary technologies to develop best-in-class products in the emerging field of immuno-oncology. The company's product candidates, based on gene-edited T-cells that express chimeric antigen receptors, or CARs, seek to harness the power of the immune system to target and eradicate cancers. Cellectis believes that CAR-based immunotherapy is one of the most promising areas of cancer research, representing a new paradigm for cancer treatment. The company is designing next-generation immunotherapies that are based on gene-edited CAR T-cells.

Cellectis Headquarter Location

8 rue de la Croix Jarry

Paris, 75013,

France

33181691600

Latest Cellectis News

Monthly information on share capital and company voting rights

Jan 11, 2022

About Cellectis  Cellectis is a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies. Cellectis utilizes an allogeneic approach for CAR-T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients, and a platform to make therapeutic gene editing in hemopoietic stem cells for various diseases. As a clinical-stage biopharmaceutical company with over 22 years of expertise in gene editing, Cellectis is developing life-changing product candidates utilizing TALEN®, its gene editing technology, and PulseAgile, its pioneering electroporation system to harness the power of the immune system in order to treat diseases with unmet medical needs. As part of its commitment to a cure, Cellectis remains dedicated to its goal of providing lifesaving UCART product candidates for multiple cancers including acute myeloid leukemia (AML), B-cell acute lymphoblastic leukemia (B-ALL) and multiple myeloma (MM). HEAL is a new platform focusing on hemopoietic stem cells to treat blood disorders, immunodeficiencies and lysosomal storage diseases. Cellectis’ headquarters are in Paris, France, with locations in New York, New York and Raleigh, North Carolina. Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS). AlloCAR T™ is a trademark of Allogene Therapeutics, Inc. For more information, visit  www.cellectis.com      Follow Cellectis on social media: @cellectis, LinkedIn and YouTube. For further information, please contact:  Media contacts:  Margaret Gandolfo, Senior Manager, Communications, +1 (646) 628 0300  Investor Relation contact:  Ashley R. Robinson, LifeSci Advisors, +1 617 430 7577, arr@lifesciadvisors.com Forward-looking Statements This press release contains “forward-looking” statements within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by words such as “anticipate,” “believe,” “intend”, “expect,” “plan,” “scheduled,” “could” and “will,” or the negative of these and similar expressions. These forward-looking statements, which are based on our management’s current expectations and assumptions and on information currently available to management, including information provided by our licensed partner Allogene, include statements about Allogene’s reinitiation of its clinical trials and its advancement to the Phase 2 portion of its ALPHA2 trial of ALLO-501A; the final results of the investigation relating to the FDA’s clinical hold on Allogene’s clinical trials, including the clinical significance of the chromosomal abnormality and any relationship to gene editing technology or manufacturing; as well as our research and development projects and priorities, our pre-clinical project development efforts and the timing of our presentation of data. These forward-looking statements are made in light of information currently available to us and are subject to numerous risks and uncertainties, including with respect to the numerous risks associated with biopharmaceutical product candidate development as well as the duration and severity of the COVID-19 pandemic and governmental and regulatory measures implemented in response to the evolving situation. With respect to our cash runway, our operating plans, including product development plans, may change as a result of various factors, including factors currently unknown to us. Furthermore, many other important factors, including those described in our Annual Report on Form 20-F and the financial report (including the management report) for the year ended December 31, 2020 and subsequent filings Cellectis makes with the Securities Exchange Commission from time to time, as well as other known and unknown risks and uncertainties may adversely affect such forward-looking statements and cause our actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons why actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future. Attachment

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Research containing Cellectis

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Cellectis in 1 CB Insights research brief, most recently on Aug 31, 2021.

Article Thumbnail

Aug 31, 2021

What Is CRISPR?

Expert Collections containing Cellectis

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Cellectis is included in 3 Expert Collections, including Synthetic Biology.

S

Synthetic Biology

238 items

Companies involved in design and development of new biological parts, devices, and systems; as well as the re-design of existing biological systems.

C

Cancer

1,179 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

R

Regenerative Medicine

1,818 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

Cellectis Patents

Cellectis has filed 168 patents.

The 3 most popular patent topics include:

  • Immune system
  • Immunology
  • Clusters of differentiation
patents chart

Application Date

Grant Date

Title

Related Topics

Status

4/9/2019

1/11/2022

Molecular biology, Transcription factors, Biotechnology, Genetics, DNA

Grant

Application Date

4/9/2019

Grant Date

1/11/2022

Title

Related Topics

Molecular biology, Transcription factors, Biotechnology, Genetics, DNA

Status

Grant

Cellectis Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Cellectis Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.